PXL-770
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase 2-readyAcquired March 2026
Key Facts
Indication
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase
Phase 2-ready
Status
Acquired March 2026
Company
About Scynexis
Scynexis has successfully transitioned to a commercial-stage biotech with the FDA approval of BREXAFEMME® (ibrexafungerp) for vulvovaginal candidiasis, now exclusively licensed to GSK. Its core innovation is the fungerp platform, a first-in-class triterpenoid antifungal with a novel mechanism of action. The company's strategy involves leveraging partnerships for commercialization while advancing a next-generation pipeline, including SCY-247, to tackle life-threatening, drug-resistant invasive fungal infections and, following a recent acquisition, exploring new therapeutic areas like polycystic kidney disease.
View full company profileTherapeutic Areas
Other Autosomal Dominant Polycystic Kidney Disease (ADPKD) Drugs
| Drug | Company | Phase |
|---|---|---|
| Oxypurinol (XRX-OXY) | XORTX Therapeutics | Phase 3 |
| Undisclosed | GondolaBio | IND Enabling |
| Undisclosed Program | Calico | Phase 2 |
| Small Molecule Corrector Program | Renasant Bio | Pre-clinical |
| Small Molecule Potentiator Program | Renasant Bio | Pre-clinical |
| AL1311 | AceLink Therapeutics | Preclinical |
| PDE4 Allosteric Modulator Program | Mironid | Pre-clinical |
| Tolvaptan | Otsuka Holdings | Approved |